Compare Becton Dickinson and Co (BDX) vs Five9 Inc (FIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Five9 Inc — how do they compare? Becton Dickinson and Co trades at $155.74 (market cap $41.51B), while Five9 Inc trades at $24.86 (market cap $1.96B). The key difference: Becton Dickinson and Co is far larger — about 21.2× Five9 Inc's market cap, and Becton Dickinson and Co pays a 2.79% dividend while Five9 Inc pays none. Which is the better fit depends on your goals.
| BDX | FIVN | |
|---|---|---|
Market Cap | $41.51B | $1.96B |
Sector | Health | Technology |
52-Week High | $185.39 | $29.16 |
52-Week Low | $135.49 | $13.61 |
Enterprise Value | $57.97B | $2.03B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Five9 (FIVN) trades at $25.81, up 1.53% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong revenue growth, improving profitability, and consistent earnings beats. Recent news includes new executive appointments and AI product launches, alongside ongoing shareholder litigation concerns. Analyst consensus is bullish with a $27.00 price target.
Outlook is positive given earnings momentum and AI-driven growth, but risks include legal overhangs and competitive pressures. The stock offers upside to consensus targets if execution continues, though high valuation multiples require sustained growth to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →
